News for AstraZeneca PLC (AZN.L)

AstraZeneca PLC (NASDAQ:AZN) Q1 2025 Earnings Conference Call April 29, 2025 6:45 AM ETCompany ParticipantsAndy Barnett - Head of IRPascal Soriot -...

U.S. stock futures are trading flat on Tuesday early-morning, keeping with the broad index averages on Monday, as markets await clarity and more earnings reports to come in over the course of this week.

U.S. stock futures rose Tuesday morning as investors looked ahead to upcoming earnings reports and awaited greater market clarity throughout the week. Things haven’t moved all that much on the trade and tariffs front, with Treasury Secretary Scott Bessent merely stating on Monday that it was up to China to “de-escalate” trade tensions. Bessent also hinted at a potential trade deal with India, saying that “it would be one of the first deals we would sign,” which investors will be watching closely

Baron International Growth Fund increased in the first quarter of 2025, although it underperformed its benchmark, the MSCI ACWI ex USA Index. Read more here.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given a positive nod, recommending an update to the marketing authoriz

OpenAI, a leader in the artificial intelligence sector, is projecting significant revenue growth over the next decade. According to internal documents, the comp

TempusAI (TEM) has seen a rise in its stock following the announcement of a significant $200 million expansion in its strategic partnership with AstraZeneca (AZ

TempusAI (TEM) has embarked on long-term collaborations with AstraZeneca (AZN) and Pathos AI, Inc., focusing on the creation of a comprehensive multimodal found

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced multi-year, stra

AstraZeneca (AZN), in collaboration with Daiichi Sankyo, has announced promising interim results from the phase 3 DESTINY-Breast09 trial involving Enhertu. In t

Focus on oncology, cardiovascular, and respiratory therapeutic areas.Strong pipeline with multiple late-stage clinical trials.Risks include regulatory challeng

We recently published a list of 10 Best UK Stocks to Buy According to Billionaires. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best UK stocks to invest in. Like most of the world, the United Kingdom is also facing slower economic growth in 2025, […]

Shares of AstraZeneca PLC (AZN) fell 4.47% in mid-day trading on Apr 9. The stock reached an intraday low of $61.24, before recovering slightly to $62.00, d

AstraZeneca's (AZN) shares decline 4.9% amid looming U.S. tariffs on pharmaceutical imports. Analysts forecast a strong price target, suggesting signifi

Key Highlights: AstraZeneca (AZN) shows substantial growth prospects with strategic acquisitions, targeting $80 billion in sales by 2030. Analysts predic

President Donald Trump has declared that his administration is on the brink of imposing a significant tariff on pharmaceuticals imported from foreign countries.

AstraZeneca (AZN) shares increased by 8% last quarter, bolstered by key EU drug approvals. Analysts forecast a potential upside of 34.49% with an averag

AstraZeneca's Imfinzi receives EU approval for NSCLC treatment with chemotherapy. Analysts predict a potential 34.49% upside for AstraZeneca stock. C

AstraZeneca and Daiichi Sankyo secure EU approval for Enhertu, expanding treatment options for breast cancer patients. Analysts forecast significant ups